Skip to content

Clinical Evaluation and Study of Huangqi Decoction in Treating Severe Fatigue in Primary Biliary Cholangitis

Clinical Evaluation and Study of Huangqi Decoction in Treating Severe Fatigue in Primary Biliary Cholangitis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003160
Enrollment
Unknown
Registered
2020-03-26
Start date
2021-05-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Biliary Cholangitis

Interventions

Sponsors

Shuguang Hospital affiliated to Shanghai University of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Ages 18-65 years, regardless of gender; 2. Meet the diagnostic criteria of primary bile cholangitis, that means, after excluding viral hepatitis, the patient must meet at least two of the following three criteria: (1) serum alkaline phosphatase (ALP) is elevated; (2) Anti-mitochondrial antibody (AMA) and / or AMA-M2 is positive; (3) liver biopsy: histological evidence of non-purulent destructive cholangitis and interlobular bile duct destruction 3. Comply with the moderate to severe assessment standards in the fatigue self-assessment scale; 4. Course of disease >= 1 year; 5. The subject or his guardian agrees enrolment in the randomized controlled trials and signs the informed consent.

Exclusion criteria

Exclusion criteria: 1. Other conditions that the researcher consider not suitable for enrollment. 2. With liver disease caused by alcohol, drugs or other reasons; 3. Liver imaging suggests a large bile duct obstruction; 4. Patients with severe heart, lung, kidney and other organ diseases; 5. Incomplete information, which affects effectiveness and safety judgment; 6. Patients with combined autoimmune hepatitis; 7. Poor compliance; 8. Pregnant and lactating women; 9. Patients with end-stage complications such as infection and massive refractory ascites; 10. Patients who are allergic to Astragalus, Licorice and ursodeoxycholic acid.

Design outcomes

Primary

MeasureTime frame
liver function;

Secondary

MeasureTime frame
Coagulation function;Ultrasound;blood test;kidney function;urine test;Fibroscan;

Countries

China

Contacts

Public ContactShili Jiang

Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine

jiangwhite@126.com+86 13917074505

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026